drugset / Trial / NCT02968121
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
Phase 1
Terminated
22 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
H. Lundbeck A/S · collab
RandomizedParallel-groupOpen-labelHealth-services research
Summary
To determine the pharmacokinetics, safety and tolerability of brexpiprazole administered subcutaneously or intramuscularly in adults with schizophrenia.
Timeline
- Start
- 2017-01
- Primary completion
- 2017-12-14
- Completion
- 2017-12-14
Outcome
Outcome not reported
Stopped: “Part A of study was completed per protocol. Conduct of Part B of the study (confirmatory phase) was not necessary.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexpiprazole | Small molecule | — | Subcutaneous |